La Nua Day Hospital Mental Health Centre
- Address
- lock Available on a paid plan
Psychiatry and Psychology – Mental Disorders
The La Nua Day Hospital Mental Health Centre is dedicated to advancing care for severe mental health conditions, focusing on both treatment‑resistant depression and post‑traumatic stress disorder. Research aims to test new therapeutic options while ensuring patient safety.
- Evaluation of innovative pharmacologic agents for depression
- Safety and tolerability studies of novel compounds for PTSD
- Combining medication with structured psychological support
Ongoing projects seek to improve outcomes for adults who have not responded to standard treatments, offering hope for more effective management.
Treatment‑Resistant Depression Research
Investigators are exploring how adding targeted medication to existing psychological support can reduce depressive symptoms in patients whose illness persists despite conventional therapy.
- Assessing symptom improvement over a six‑week period
- Comparing different dosage levels of investigational agents
- Monitoring patient‑reported outcomes and functional recovery
The goal is to identify strategies that provide faster and more durable relief for those struggling with chronic depression.
Post‑Traumatic Stress Disorder Studies
A separate trial evaluates the safety of a weekly oral compound and its potential to alleviate core PTSD symptoms when combined with therapeutic guidance.
- Weekly administration over a four‑week safety monitoring period
- Measuring changes in trauma‑related anxiety and intrusive memories
- Integrating clinical observation with patient feedback
Findings aim to expand treatment options for individuals living with the lasting impacts of traumatic experiences.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Cybin IRL Limited2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Cybin IRL Limited2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 45 other sites in Ireland
Therapeutic Area Benchmark — Ireland
Select a therapeutic area to compare against other sites in Ireland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Ireland
Market Share
Country: Ireland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in La Nua Day Hospital Mental Health Centre
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Psilocybin (COMP360) in Adults with Treatment-Resistant Depression: A Phase III Randomized, Double-Blind, Controlled Trial | Compass Pathfinder Limited | Phase III | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Methylone | 2 | Unknown | 2024-01-16 | 2024-06-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.